Examination of a preclinical study testing late-life muscle-targeted gene delivery of a metabolic protein and its effects on aging outcomes.
Key Takeaways
- Researchers delivered FGF21 to muscle using a viral vector late in life
- Median lifespan in treated male mice increased by about 20%
- Treated mice showed improvements across multiple healthspan markers